Loading insights library...
Curated Multi-Media Intelligence
Institutional Insights Library
A curated library of professional podcasts, investment blogs, and primary source insights from sophisticated institutional managers.
InsightSUBSTACKApril 27, 202615 min read
(•‿-) Earnings forecast 4Q. 2025 – Hydreight $NURS. V $HYDTF – From "Uber for nurses" to "Shopify of Digital Healthcare" – why Q4 2025 could be the gamechanger quarter
By ppinvest007
Primary Source Material
Published via ppinvest007
Thanks for reading! Subscribe for free to receive new posts and support my work.
1. Assessment
In anticipation of the upcoming release of audited financial results for the fourth quarter of 2025 and the full fiscal year 2025, Hydreight Technologies Inc. (TSXV: NURS, OTCQB: HYDTF) is in a fundamental and highly disruptive phase of transformation. The company, which originally began as a mobile-only care network for intravenous infusion therapies and on-site healthcare services, has evolved into a full-fledged back-end infrastructure for digital healthcare providers through the aggressive technological scaling of its proprietary platforms. Dubbed the “Shopify of Digital Healthcare” by management, Hydreight now empowers third-party clinics, entrepreneurs and traditional retailers to launch their own direct-to-consumer (D2C) telehealth brands in all 50 U.S. states in a matter of days.
The quantitative probability that Hydreight Technologies will exceed current market forecasts for sales and earnings in the fourth quarter of 2025 is estimated at 75% as part of this analysis. The probability of an “in-line” result, in which the consensus expectations are only met with pinpoint accuracy, is assessed at 15%. In view of the available empirical preliminary data points, a failure to meet the forecasts is considered highly unlikely and is estimated at only 10%.
The current market consensus for the fourth quarter of 2025 is for revenue of approximately CAD 15.09 million. However, on February 2, 2026, the Company issued a formal and “conservative” baseline guidance for the immediately following first quarter of 2026 (Q1 2026) of CAD 25 million to CAD 28 million. To justify such a steep run rate for the first quarter of 2026, the fourth quarter of 2025 must act as a logical and continuous growth bridge. Sequential revenue growth that only reaches the consensus of CAD 15.09 million in the fourth quarter would imply an implausibly abrupt jump in revenue of nearly 80% between the fourth quarter of 2025 and the first quarter of 2026. The company announcements, according to which more than 1.3 million product orders had already been processed by December 18, 2025, thus exceeding the operating target for the year ahead of schedule, strongly indicate that the acceleration in growth was already deeply anchored in the fourth quarter of 2025 and that the run rate must have significantly exceeded consensus estimates.
Scenario model and simulated market reaction
The following scenario model simulates the likely immediate price reactions of Hydreight shares when the quarterly figures are released, depending on which grid the actual fundamental results and metrics fall into. The model takes into account the current discrepancy between the market capitalization and the projected growth path.
The significant upward reaction in the event of outperformance is facilitated by the fact that management has installed a comprehensive share buyback program (Normal Course Issuer Bid, NCIB) in parallel, which came into force on March 12, 2026 and authorizes the purchase of up to 4,951,189 ordinary shares (approximately 10% of the public free float). A strong quarterly result, combined with the systematic buying pressure from the NCIB and the re-evaluation of the multiples by institutional investors, is likely to be a significant catalyst for the share price’s performance.
The key drivers underpinning these forecasts are a complex mix of operational, strategic, and capital markets factors. On the positive side, exponential revenue growth is primarily driven by the VSDHOne platform. This was launched in June 2025 and went through its second full quarter of commercial revenue recognition in the fourth quarter of 2025. The platform overcomes the regulatory barriers to entry of the U.S. healthcare market by bundling all compliance, healthcare professionals, e-commerce technology, and a nationwide 503A and 503B pharmacy network into one modular SaaS offering. Another highly potent driver is the company’s multi-vertical strategy. Unlike many peers in the telemedicine sector, Hydreight is not a pure-play GLP-1 (weight loss drug) business, as these treatments currently account for only about 28% of the total platform activity. The company is experiencing growth in the Testosterone Replacement Therapy (TRT), Peptide Therapy, NAD+ Infusions, Hair Loss Treatments, and Sexual Health Services segments.
In addition, the aggressive market entry into the home testing sector for sexually transmitted diseases (STIs) on December 31, 2025 acts as an additional revenue catalyst. With 50,000 pre-orders generated from a standing start, Hydreight is tapping into a high-margin revenue stream that will be fully reflected in the books in the first quarter of 2026. The strategic capital position was massively strengthened in January 2026 by an oversubscribed “bought deal” LIFE-Offering (Listed Issuer Financing Exemption) of CAD 15 million at an issue price of CAD 4.05 per unit. This financing round, led by Canaccord Genuity and Beacon Securities, resolves any short-term liquidity risk and enables the unchecked scaling of production capacities and platform rollouts.
On the negative side, there are driving factors that could temporarily dampen margin expansion. The upfront investment in the development of the VSDHOne 2.0 architecture, which aims to achieve even greater automation and scalability in B2B onboarding, requires significant capital investment. In addition, hypergrowth is forcing the company to drastically increase spending on marketing and support infrastructure in order to maintain the network effect between nurses, patients, and pharmacies. Although the company has crossed the profitability threshold, the absolute pace of scaling to a projected annual revenue of CAD 150 million in 2026 could put pressure on the adjusted EBITDA margin in individual intermediate quarters if operating fixed costs increase faster than expected.
A clear picture emerges regarding the future risks and opportunities that dominate the outlook for Hydreight. The most significant opportunity lies in the roll-off of the initial discounts. To accelerate the adoption of the VSDHOne platform at launch in the summer of 2025, incentive pricing has been granted to early B2B partners. The expiration of these discounts in the fourth quarter of 2025 and first quarter of 2026 offers a huge opportunity for asymmetric gross margin expansion while maintaining the same transaction volume.
The vertical integration of the supply chain through the acquisition of a 5% stake in Perfect Scripts Pharmacy in November 2025, including an option to increase to 40%, also gives the company direct control over input costs in the pharmacy business and shields it from external price shocks.
The primary risk in this expansive construct is classic operational execution risk. The extremely fast onboarding of hundreds of B2B customers requires an error-free software architecture and uncompromising compliance in a highly regulated environment.
U.S. state regulatory interventions regarding telehealth prescribing practices remain a systemic risk, although Hydreight’s legal framework is explicitly designed to navigate this complexity in all 50 states in a legally secure manner.
2. Key figure (revenue, EBITDA, profit)
Hydreight closed fiscal 2024 with positive adjusted EBITDA of $490,000 and consistently expanded that operating profitability across all reported quarters of 2025, with adjusted EBITDA of $620,000 in the third quarter of 2025 alone. The forward-looking EBITDA margin for 2026 is estimated by management to be between 15% and 17% of projected revenue, which would translate to absolute operating cash flow of over $22 million.
GAAP net income is the ultimate indicator of financial health, strictly adhering to all regulatory accounting requirements. Unlike many comparable digital health platforms that buy growth through deep red balance sheets, Hydreight has proven that hypergrowth and GAAP profitability can coexist. The company reported GAAP net income of $362,000 in the third quarter of 2025, compared to a net loss of just under $90,000 in the same quarter last year. This series of now four consecutive profitable quarters underscores management’s operational discipline.
Gross margin is also presented in a GAAP and adjusted version. Adjusted gross margin is defined as GAAP gross margin plus inventory impairment and deferred revenue from contracts with business partners. In the third quarter of 2025, GAAP gross margin was $2.33 million, an increase of 52% year over year. The continued expansion of this margin will be critical to how quickly the company can scale higher-value medical categories (such as genetics, GLP-1, and STI testing) through the VSDHOne platform and how effective automation (VSDHOne 2.0) is at reducing partner onboarding costs.
3. Consensus forecast (current quarter/half-year)
Capital market analysts’ consensus forecast for the fourth quarter of 2025 illustrates an intriguing divergence between historical estimation models and the actual operational reality communicated by the company in real time. For the reporting quarter ended December 31, 2025, the average estimate of the analysts’ guild is for total revenue of $15.085 million to $15.09 million. On the earnings side, the market expects earnings per share (EPS) of $0.02 for the fourth quarter.
These consensus numbers are formed by a group of renowned North American investment banks and analyst firms, including Canaccord Genuity, Beacon Securities, and Maxim Group, among others. Analysts have significantly revised their price targets upwards in the months leading up to April 2026, with the average 12-month price target currently priced in a range of $9.75 to $9.95. Measured by a share price fluctuating between $3.95 and $4.20 in the run-up to the figures, the analyst consensus implies a massive fundamental undervaluation of nearly 57%, or an upside potential of over 130%. Canaccord Genuity, for example, explicitly initiated the coverage of the stock with a “buy” rating, emphasizing the moat Hydreight has built through its network of over 3,000 nurses, 300 physicians, and the integrated 503A/503B pharmacy network.
In order to evaluate the plausibility of the Q4 consensus forecast of CAD 15.09 million, the analyst bias must be considered in the context of corporate communications from February 2026. On February 2, 2026, Hydreight published a formal financial guidance that electrified the market environment: For the first quarter of 2026 (Q1 2026), management expects revenues in the range of CAD 25 million to CAD 28 million. In parallel, an annual forecast for the fiscal year 2026 of around CAD 150 million was issued. The management around CEO Shane Madden expressly emphasized that this 150 million mark is to be understood as a “conservative floor case scenario”. It is based exclusively on existing partner relationships, currently active customer programs and the use of existing infrastructure. Potential revenues from future acquisitions, expansion into new international markets or new corporate partnerships that were not yet operational at the time of the announcement in February were completely excluded.
The discrepancy becomes obvious here: If Hydreight generated GAAP revenue of CAD 10.52 million in the third quarter of 2025 and conservatively expects at least CAD 25 million for the first quarter of 2026, then the fourth quarter of 2025 must be the logical and gradual link in this steep growth curve. The analysts’ forecast of CAD 15.09 million seems extremely conservative against this backdrop, as it assumes that the majority of the growth leap would not occur until post-December 2025. However, the empirical data, such as exceeding the mark of 1.3 million processed product orders in mid-December 2025 ahead of schedule, speak a contrarian language.
They indicate that the acceleration in growth on the VSDHOne platform is likely to have pushed transaction volume well above the consensus mark of CAD 15 million as early as the fourth quarter. Consensus lags behind operational reality, a phenomenon often seen in hyper-growing micro-cap technology stocks, as analysts often readjust their models structurally only after the publication of audited results.
4. Comparison of the previous quarter
The immediately preceding third quarter of 2025 (Q3 2025), which ended on September 30 and was communicated at the end of November 2025, marked a historic turning point in Hydreight Technologies’ operating performance. It acts as the crucial benchmark against which the results of the fourth quarter are measured.
Was the previous quarter strong or weak? The third quarter of 2025 was an exceptionally strong record quarter by all objective measures of financial analysis. The company experienced hyperinflationary revenue growth, which impressively demonstrated the viability of its business model. Topline revenue escalated to CAD 12.83 million, a massive increase of 110% compared to the same quarter last year. Even more impressive was the development of GAAP revenue, which reached CAD 10.52 million, registering a growth of 132% year-over-year.
Margin and profitability metrics also followed this positive trend vector. GAAP gross margin expanded by 52% to CAD 2.33 million (compared to CAD 1.53 million in Q3 2024). On an operational level, Hydreight generated adjusted EBITDA of CAD 620,000. Final GAAP net income was CAD 362,000, which was a remarkable turnaround compared to the net loss of CAD 90,000 in the third quarter of the previous year. The balance sheet structure was also extremely robust at the end of the third quarter, with the company having cash on hand of CAD 18.64 million and operating completely debt-free.
Looking at the first nine months of 2025 cumulatively, topline revenue was $26.71 million (up 61% year-over-year), while GAAP revenue climbed to $20.44 million (up 70% year-over-year).
Were there any special features or special effects? The most serious special effect that characterized the third quarter of 2025 and acts as a structural catalyst for the future was the first-time, full-scale recognition of revenues from the newly launched VSDHOne platform. While the first customers went through the complex, multi-month onboarding process (due to state and federal regulations) in late spring, they began to process substantial orders via the platform for the first time in June 2025. The third quarter thus benefited as the first quarter from the full commercial leverage of this D2C SaaS model. Management quantified this effect precisely: a remarkable 57% of the total revenue growth in the quarter was directly attributable to the new contributions of the VSDHOne platform.
In addition to VSDHOne, the underlying metrics of the underlying underlying business showed strong anomalies in a positive sense. Pharmacy order volumes increased by 72% year-on-year, reflecting a high rate of recurring use, treatment continuity, and broader adoption of categories such as TRT (testosterone replacement therapy) and peptides. The platform’s network effect also accelerated, with new nurse sign-ups up 49% year-over-year in the third quarter, and as much as 63% year-over-year on a nine-month basis (593 registrations compared to 364 last year).
5. Comparison of the same quarter and half-year of the previous year
In order to holistically understand the exponential speed and scale of Hydreight Technologies’ transformation, a detailed comparison with the corresponding quarter of the previous year (Q4 2024) as well as the entire fiscal year 2024 is essential. This historical perspective illustrates the transition from an emerging startup to a cashflow-positive platform ecosystem.
Was it strong or weak? From a historical perspective at the time, the fourth quarter of 2024 was considered exceptionally strong and a “milestone quarter” by analysts and management. It was the quarter that Hydreight finally crossed the Rubicon to profitability and generated positive operating cash flow. Topline revenue was $5.74 million in the fourth quarter of 2024, representing a solid 15% growth over Q4 2023. GAAP revenue was $4.04 million, an increase of 20% year-over-year. GAAP gross margin for the period was $1.37 million. On the earnings side, the company posted adjusted EBITDA of $270,000 in Q4 2024, which was a notable fundamental improvement from the EBITDA loss of $557,000 in the fourth quarter of 2023.
For the full fiscal year 2024, the record figures accumulated: topline revenue reached CAD 22.32 million (up 31% from 2023), GAAP revenue rose to CAD 16.04 million (up 39% from 2023), and closed the year with positive adjusted EBITDA of CAD 490,000 (a drastic turnaround from the loss of CAD 1.38 million in 2023).
Were there any special features or special effects? The primary feature of the fourth quarter of 2024 was the financial proof of concept. Achieving structural profitability eliminated the need for dilutive emergency financing, which is endemic to the early-stage digital health sector. This milestone opened up access to institutional capital for Hydreight and ultimately led to the company being included in Deloitte’s prestigious “2024 Technology Fast 50” list (as the 9th fastest growing company in Canada) as well as the top 50 of the TSX Venture Exchange.
If you now compare the metrics of Q4 2024 with the expectations for Q4 2025, the tectonic extent of the business expansion becomes evident. While GAAP revenue of just over CAD 4 million was generated in the fourth quarter of 2024, the analyst consensus projects revenue of around CAD 15 million for the fourth quarter of 2025 – with the internal guidance for Q1 2026 even targeting CAD 25 million to CAD 28 million. This means that quarterly revenue has almost quadrupled in just twelve months.
The underlying structural special effect that explains this discrepancy between 2024 and 2025 is the radical evolution of the business model. In 2024, Hydreight generated its revenue primarily as an enablement platform for independent caregivers and traditional brick-and-mortar clinics that wanted to offer mobile infusion services (white-label locations). It was a solid but linearly growing B2B business. During 2025, the company pivoted to VSDHOne – a direct-to-consumer SaaS platform. By offering a fully integrated backend solution that combines physician networks, telemedicine software, and pharmacy fulfillment, Hydreight was suddenly able to aggregate the total recurring prescription revenue and platform fees of hundreds of new D2C healthcare brands. This shift from a linear B2B service to an exponentially scalable D2C ecosystem is the isolated fundamental reason why Q4 2024 looks tiny in retrospect compared to what is expected in Q4 2025 and in 2026.
Conclusion: The quarterly figures should come soon. I expect a positive surprise and am positioned accordingly.
Thanks for reading! This post is public so feel free to share it.
Share
Disclaimer
This text was partly created with AI applications.
All content is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities or other financial market instruments. Of course, I try to present the facts to the best of my knowledge and belief, but they can still be false in whole or in part.
Therefore, I do not accept any liability for investment decisions that you make on the basis of the information presented here.
Conflict of interest: At the time of publication, the author of this publication holds shares/securities of the securities/companies discussed here and intends to sell them depending on the market situation and could benefit in particular from increased trading liquidity. As a result, there is a concrete and clear conflict of interest.
Join the Intelligence Network
Institutional Research
Straight to Your Inbox
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime